Plain-English translation of NCT04176718 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing —a newer medication—combined with three other drugs (two of which are standard treatments and one that is newer) for people with multiple myeloma that has returned or stopped working with prior treatments. The goal is to see if this medication combination works better than treatments used before. You would receive all four drugs together on a 28-day cycle.
Multiple myeloma often comes back or stops responding to initial treatments, leaving patients with limited options. Researchers believe this medication combination might help people whose cancer has become resistant to earlier drugs.
You will visit the study site regularly over 28-day cycles to receive the medication combination. is given by infusion according to a set schedule; is given by infusion on specific days (days 1, 8, and 15 of each cycle); is taken as a capsule daily for 21 days; and is given weekly, split over two days. You will have blood tests and other evaluations to monitor how you are responding and to watch for side effects throughout the study.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States